List of Tables
Table 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Trends
Table 2. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers & Opportunity
Table 3. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Challenges
Table 4. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints
Table 5. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Eosinophilic Granulomatosis with Polyangiitis Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Eosinophilic Granulomatosis with Polyangiitis Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Eosinophilic Granulomatosis with Polyangiitis Treatment
Table 10. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Granulomatosis with Polyangiitis Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Genentech Basic Information List
Table 32. Genentech Description and Business Overview
Table 33. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Genentech (2019-2024)
Table 35. Genentech Recent Developments
Table 36. Roche Basic Information List
Table 37. Roche Description and Business Overview
Table 38. Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Roche (2019-2024)
Table 40. Roche Recent Developments
Table 41. Cephalon Basic Information List
Table 42. Cephalon Description and Business Overview
Table 43. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Cephalon (2019-2024)
Table 45. Cephalon Recent Developments
Table 46. Teva Pharmaceutical Industries Basic Information List
Table 47. Teva Pharmaceutical Industries Description and Business Overview
Table 48. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Teva Pharmaceutical Industries (2019-2024)
Table 50. Teva Pharmaceutical Industries Recent Developments
Table 51. Amgen Basic Information List
Table 52. Amgen Description and Business Overview
Table 53. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Amgen (2019-2024)
Table 55. Amgen Recent Developments
Table 56. Sanofi Basic Information List
Table 57. Sanofi Description and Business Overview
Table 58. Sanofi Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Sanofi (2019-2024)
Table 60. Sanofi Recent Developments
Table 61. Koninklijke DSM Basic Information List
Table 62. Koninklijke DSM Description and Business Overview
Table 63. Koninklijke DSM Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Koninklijke DSM (2019-2024)
Table 65. Koninklijke DSM Recent Developments
Table 66. AstraZeneca Basic Information List
Table 67. AstraZeneca Description and Business Overview
Table 68. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of AstraZeneca (2019-2024)
Table 70. AstraZeneca Recent Developments
Table 71. Novartis Basic Information List
Table 72. Novartis Description and Business Overview
Table 73. Novartis Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Novartis (2019-2024)
Table 75. Novartis Recent Developments
Table 76. GSK Basic Information List
Table 77. GSK Description and Business Overview
Table 78. GSK Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of GSK (2019-2024)
Table 80. GSK Recent Developments
Table 81. Baxter International Basic Information List
Table 82. Baxter International Description and Business Overview
Table 83. Baxter International Eosinophilic Granulomatosis with Polyangiitis Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Eosinophilic Granulomatosis with Polyangiitis Treatment Business of Baxter International (2019-2024)
Table 85. Baxter International Recent Developments
Table 86. Key Raw Materials Lists
Table 87. Raw Materials Key Suppliers Lists
Table 88. Eosinophilic Granulomatosis with Polyangiitis Treatment Downstream Customers
Table 89. Eosinophilic Granulomatosis with Polyangiitis Treatment Distributors List
Table 90. Research Programs/Design for This Report
Table 91. Key Data Information from Secondary Sources
Table 92. Key Data Information from Primary Sources
Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Product Picture
Figure 2. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Eosinophilic Granulomatosis with Polyangiitis Treatment Report Years Considered
Figure 5. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2023
Figure 7. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Steroids Picture
Figure 9. Immunosuppressant Picture
Figure 10. Biologics Picture
Figure 11. Immune Globulins Picture
Figure 12. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Oral
Figure 15. Product Picture of Intravenous
Figure 16. Product Picture of Intramuscular
Figure 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value (%), (2019-2030)
Figure 30. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 36. China Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 38. China Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 48. India Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Type (%), 2023 VS 2030
Figure 50. India Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Value by Application (%), 2023 VS 2030
Figure 51. Eosinophilic Granulomatosis with Polyangiitis Treatment Industrial Chain
Figure 52. Eosinophilic Granulomatosis with Polyangiitis Treatment Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
